In a new study, researchers have found that patients with diabetes who started statin therapy right away reduced the rate of heart attack and stroke by one third compared to those who chose to delay taking the medication. The results can help guide decision-making conversations between clinicians and their patients.
Taking a statin medication is an effective, safe, and low-cost way to lower cholesterol and reduce risk of cardiovascular events. Despite clinicians recommending that many patients with diabetes take statins, nearly one-fifth of them opt to delay treatment.
Heart attacks and strokes remain the leading cause of complications and mortality for patients with diabetes. Statin therapy reduces risk of these cardiovascular events by preventing plaque buildup in the blood vessels, which, once accumulated, prevents delivery of oxygen and essential nutrients to the heart and brain.
“I see patients with diabetes on a regular basis, and I recommend statin therapy to everyone who is eligible,” said senior author Alexander Turchin, of the Division of Endocrinology at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system. “Some people refuse because they want to first try lifestyle interventions or other drugs.
But other interventions are not as effective at lowering cholesterol as starting statin therapy as soon as possible. Time is of the essence for your heart and brain health.”
The researchers used an artificial intelligence method called Natural Language Processing to gather data from the electronic health records of 7,239 patients at Mass General Brigham who ultimately started statin therapy during the nearly 20-year study period. The median patient age was 55, with 51 per cent being women, 57 per cent white, and the median HbA1c – a measure of blood sugar – being 6.9.
Nearly one-fifth (17.7 per cent) of the patients in the study declined statin therapy when it was first recommended by their clinicians, then later accepted the therapy (after a median of 1.5 years) upon repeated recommendation by their clinician. Of those who delayed, 8.5 per cent had a heart attack or stroke. But for patients who started statins immediately, the rate of those cardiovascular events was just 6.4 per cent.
“Clinicians should recognise the increased cardiovascular risk associated with delaying statin therapy for patients with diabetes and use this information to guide shared decision-making conversations with their patients,” said Turchin.
